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Abstract
Background: Patients with myocardial infarction (MI) are at risk of the development of atrial 
fibrillation (AF) and ischemic stroke. We sought to evaluate the prognostic performance of the 
CHADS2 and CHA2DS2-VASc scores in predicting new AF and/or ischemic stroke in post-ST 
segment elevation MI (STEMI) patients. Six hundred and seven consecutive post-STEMI 
patients with no previously documented AF were studied.
Methods and Results: After a follow-up of 63 months (3,184 patient-years), 83 (13.7%) pa-
tients developed new AF (2.8% per year). Patients with a high CHADS2 and/or CHA2DS2-VASc 
score were more likely to develop new AF. The annual incidence of new AF was 1.18%, 2.10%, 
4.52%, and 7.03% in patients with CHADS2 of 0, 1, 2, and ≥ 3; and 0.39%, 1.72%, 1.83%, 
and 5.83% in patients with a CHA2DS2-VASc score of 1, 2, 3 and ≥ 4. The CHA2DS2-VASc 
score (C-statistic = 0.676) was superior to the CHADS2 (C-statistic = 0.632) for discrimina-
ting new AF. Ischemic stroke occurred in 29 patients (0.9% per year), the incidence increasing 
in line with the CHADS2 (0.41%, 1.02%, 1.11%, and 1.95% with score of 0, 1, 2, and ≥ 3) and 
CHA2DS2-VASc scores (0.39%, 0.49%, 1.02%, and 1.48%  with score of 1, 2, 3 and ≥ 4). The 
C-statistic of the CHA2DS2-VASc score as a predictor of ischemic stroke was 0.601, superior to 
that of CHADS2 score (0.573). CHADS2 and CHA2DS2-VASc scores can identify post-STEMI 
patients at high risk of AF and stroke.
Conclusions: The CHADS2 and CHA2DS2-VASc scores can identify post-STEMI patients at 
high risk of AF and ischemic stroke. This enables close surveillance and prompt anticoagula-
tion for stroke prevention. (Cardiol J 2014; 21, 5: 474–483)
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Introduction
Atrial fibrillation (AF) is the most common 
sustained arrhythmia encountered in clinical pra-
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of ischemic stroke [1]. Patients with established 
coronary artery disease, particularly myocardial 
infarction (MI), are at substantial risk of AF deve-
lopment [2, 3], as well as ischemic stroke. Although 
anticoagulation therapy can effectively reduce the 
risk of thromboembolism in these patients, the 
arrhythmia is often not diagnosed until the patient 
presents with an ischemic stroke, as ischemic stroke 
has been reported as the first presentation in up to 
25% of patients with AF [4]. This precludes the im-
plementation of any preventive measures including 
anticoagulation. Early identification of patients at high 
risk of AF development may thus allow close surve-
illance and prompt initiation of oral anticoagulation 
to prevent stroke. To date, several scores have been 
developed to predict AF in the general population but 
daily clinical application is difficult [5, 6].
The CHADS2 (Congestive heart failure, Hy-
pertension, Age ≥ 75 years, Diabetes, previous 
Stroke) score and more recently, the CHA2DS2-
-VASc (CHA2DS2-Vascular disease, Age 65–74 
years, Sex category) score have been validated and 
widely used for risk stratification of AF patients for 
oral anticoagulation therapy [1, 7, 8]. The individual 
score components not only predict ischemic stroke 
risk associated with AF, but have also been linked 
to the development of AF [5, 6, 9]. In this study, 
we sought to investigate whether the CHADS2 
and CHA2DS2-VASc scores can predict new-onset 




From January 1998 to December 2005, 617 
consecutive patients who previously survived 
a ST-segment elevation MI (STEMI; > 40 days) were 
referred to the Cardiac Rehabilitation and Preven-
tion Center of Tung Wah Hospital [10–14]. This is 
the largest rehabilitation facility in Hong Kong and 
serves a population of about half a million. During 
the study period, coronary revascularization was 
performed in those who survived STEMI and who 
experienced chest pain and/or ischemia inducible 
on treadmill testing. Patients were excluded from 
study if they had previously documented AF prior 
to the index MI, a positive exercise stress test sug-
gestive of residual myo cardial ischemia, New York 
Heart Association (NYHA) functional class IV, and/ 
/or other terminal illness. Informed consent was ob-
tained from all patients. The final analysis included 
607 patients who were categorized according to the 
CHADS2 and CHA2DS2-VASc scores.
Study design
This was a single center, prospective observa-
tional study, approved by the local Research Ethics 
Committee. Following recruitment to the Cardiac 
Rehabilitation Program, data pertaining to the in-
dex MI, demographics, cardiovascular risk factors, 
and medications were entered into the Tung Wah 
Hospital Cardiac Rehabilitation Program Database. 
All patients underwent baseline exercise stress 
tests and echocardiography, and were prospecti-
vely followed up in our cardiac outpatient clinic. 
All patients were also followed up in the Cardiac 
Rehabilitation Program once every 3 months. The 
presence of AF was defined as the presence of 
fibrillatory P waves with irregular R-R intervals 
for > 5 beats at rest or on 24 h electrocardiogram 
(ECG) recording. The occurrence of new-onset AF 
and/or ischemic stroke within the follow-up period 
was retrieved from the medical records and dis-
charge summaries from the territory wide informa-
tion network of all public hospitals in Hong Kong. 
The primary endpoint of new occurrence of clinical 
AF was defined as the presence of AF documented 
by resting 12-lead ECG. The secondary endpoint 
was ischemic stroke during the follow-up period. 
Ischemic stroke was defined as a neurological defi-
cit of sudden onset that persisted for more than 24 h 
and corresponded to a vascular territory in the 
absence of primary hemorrhage, and that could not 
be explained by other causes (trauma, infection, 
vasculitis). Stroke was confirmed by computerized 
axial tomography or magnetic resonance imaging 
of the brain [15, 16].
Statistical analysis
Continuous and discrete variables are expres-
sed as mean ± standard derivation and percentages, 
respectively. Statistical comparisons of the baseli-
ne clinical characteristics were performed using 
Student’s t-test, one-way ANOVA or Fisher’s exact 
test, as appropriate. Kaplan-Meier survival analyses 
with the log-rank test were carried out and the Cox 
proportional hazards regression model was used to 
calculate the hazard ratios (HRs) of some predictive 
factors and their 95% confidence intervals (CIs) for 
the incidence of new AF and ischemic stroke.
For descriptive purposes, patients were classi-
fied into strata according to the CHADS2 (CHADS2 = 0, 
CHADS2 = 1, CHADS2 = 2, and CHADS2 ≥ 3) 
and CHA2DS2-VASc scores (CHA2DS2-VASc ≥ 1, 
CHA2DS2-VASc = 2, CHA2DS2-VASc = 3, CHA2DS2- 
-VASc ≥ 4). The prognostic performance of the 
CHADS2 and the CHA2DS2-VASc scores with 
regard to AF and ischemic stroke was assessed 
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using area under the curve (C-statistic) for recei-
ver operating characteristic curve calculated using 
Analyze-It for Excel with Delong-Delong compa-
rison for C-statistic. The C-statistic integrates 
measures of sensitivity and specificity of the range 
of a variable. Ideal prediction yields a C-statistic of 
1.00, whereas a value of < 0.5 reflects a prediction 
ability no better than chance. Calculations were 
performed using SPSS software (version 12.0) 
and MedCalc software. All tests were two-sided, 
and p-values were considered significant if < 0.05.
Results
A total of 607 post-MI patients with no pre-
viously documented AF were recruited. Tables 1 
and 2 summarize the clinical characteristics across 
the strata of CHADS2 and CHA2DS2-VASc sco-
res, respectively. As expected, the CHADS2 and 
CHA2DS2VASc scores were strongly associated with 
each of the components constituting the scores. Spe-
cifically, compared with patients with low CHADS2 
score, the group of patients with a high score was 
older (p < 0.01), and had a higher proportion of 
females (p < 0.001), hypertension (p < 0.001) and 
diabetes mellitus (p < 0.001). In addition, these 
patients were more likely to have renal impairment 
(p < 0.01) and a lower left ventricular ejection fra-
ction (LVEF; p < 0.01), and be prescribed statin the-
rapy (p < 0.01). Similar trends were also observed 
in the CHA2DS2-VASc group (Table 2).
New-onset atrial fibrillation
After a mean follow-up of 63 ± 44 months 
(3,184 patient-years), new-onset clinical AF was 
detected in 83 patients (13.7%, 2.80 per 100 
patient-years). Patients with new-onset AF were 
older (70.2 ± 7.8 vs. 63.8 ± 11.7 years, p < 0.001), 
were more likely to be female (39.5% vs. 22.5%, 
p = 0.001), and had a higher prevalence of heart 
failure (31.3% vs. 12.0%, p < 0.001), but lower 
prevalence of hypercholesterolemia (43.4% vs. 
58.0%, p = 0.01), and a lower LVEF (42.0 ± 9.6% 
vs. 46.2 ± 10.2%, p = 0.001; Table 3). In addition, 
patients with new-onset AF were less likely to be 
prescribed beta-blocker therapy (53.0% vs. 76.0%, 
p < 0.001) or statins (59.0% vs. 76.5%, p = 0.001). 
Patients with new-onset AF also had a significan-
tly higher mean CHADS2 score (1.71 ± 1.04 vs. 
1.21 ± 0.98, p < 0.0001) and mean CHA2DS2-VASc 
score (3.90 ± 1.34 vs. 2.97 ± 1.40, p < 0.001) than 
those without AF (Table 3).
Table 4 summarizes the baseline demographic 
factors, the CHADS2 and CHA2DS2-VASc scores; and 
Table 1. Baseline characteristics of patients stratified according to the CHADS2 score.
CHADS2 score
0 (n = 155) 1 (n = 203) 2 (n = 181) ≥ 3 (n = 68) P
Age [years] 58.1 ± 10.6 64.2 ± 10.8 66.7 ± 10.4 76.0 ± 6.8 < 0.001*
Female gender 15 (9.7%) 47 (23.2%) 62 (34.3%) 27 (39.7%) < 0.001*
Hypertension 0 (0%) 101 (49.8%) 156 (86.2%) 60 (88.2%) < 0.001*
Diabetes mellitus 0 (0%) 55 (27.1%) 127 (70.2%) 54 (79.4%) < 0.001*
Heart failure 0 (0%) 13 (6.4%) 35 (19.3%) 41 (60.3%) < 0.001*
Hypercholesterolemia 71 (45.8%) 92 (45.3%) 75 (41.4%) 29 (42.6%) 0.83
Lung disease 17 (11.0%) 22 (10.8%) 14 (7.7%) 5 (7.4%) 0.61
Significant renal impairment 4 (2.6%) 19 (9.4%) 17 (9.4%) 11 (16.2%) < 0.01*
Left ventricular ejection fraction [%] 47.0 ± 9.6 46.4 ± 10.1 44.8 ±10.4 42.3 ± 10.8 < 0.01*
Revascularization:
PCI 25 (16.1%) 33 (16.3%) 30 (16.6%) 12 (17.6%) 0.99
CABG 1 (0.6%) 2 (1.0%) 2 (1.1%) 0 (0%) 0.83
Medications:
Aspirin 150 (96.8%) 189 (93.1%) 167 (92.3%) 63 (92.6%) 0.34
ACEI 119 (76.8%) 164 (80.8%) 145 (80.1%) 52 (76.5%) 0.74
Beta-blockers 109 (70.3%) 154 (75.9%) 135 (74.6%) 44 (64.7%) 0.26
Statin 5 (3.2%) 14 (6.9%) 20 (11.0%) 10 (14.7%) < 0.01*
Calcium channel blocker 119 (76.8%) 146 (71.9%) 141 (77.9%) 44 (64.7%) 0.13
*p < 0.05; PCI — percutaneous coronary intervention; CABG — coronary artery bypass grafting; ACEI — angiotensin-converting-enzyme inhi-
bitor; CHADS2 score — Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes, previous Stroke score
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their corresponding HRs and 95% CIs that were as-
sociated with new-onset AF based on a Cox propor-
tional hazards model. Amongst these parameters, 
age ≥ 65, age ≥ 75, female gender, hypertension, 
diabetes mellitus, heart failure, previous stroke, as 
well as the CHADS2 and CHA2DS2-VASc scores were 
strongly associated with new-onset AF (Table 4). 
Kaplan-Meier analysis revealed a significantly 
higher incidence of new-onset AF in patients with 
higher CHADS2 score (Log-rank: 21.5, p < 0.0001, 
Fig. 1A) and higher CHA2DS2-VASc score (Log-
-rank: 31.4, p < 0.0001, Fig. 1B). Patients with 
a higher CHADS2 or CHA2DS2-VASc score were 
much more likely to develop new-onset AF than 
those with a lower score. The corresponding inci-
dence of new-onset AF was 1.18 per 100 patient-
-years in patients with CHADS2 = 0; 2.10 per 100 
patient-years in patients with CHADS2 = 1; and 4.52 
per 100 patient-years in those with CHADS2 = 2; 
7.03 per 100 patient-years in those with CHADS2 
≥ 3. The incidence of new-onset AF also increased 
with the CHA2DS2-VASc score: CHA2DS2-VASc = 1: 
0.39 per 100 patient-years; CHA2DS2-VASc = 2: 
1.72 per 100 patient-years; CHA2DS2-VASc = 3: 
1.83 per 100 patient-years; and CHA2DS2-VASc ≥ 4: 
5.83 per 100 patient-years.
To compare the prognostic performance of the-
se parameters, within the CHADS2 and CHA2DS2- 
-VASc scores, in predicting new-onset AF, the sens-
itivity, specificity and C-statistic for the CHADS2 
and CHA2DS2-VASc scores in relation to new-
-onset AF were determined (Table 5). Among all 
these factors, test discrimination of the CHA2DS2- 
-VASc score (C-statistic = 0.676) was superior to 
the CHADS2 (C-statistic = 0.632) and age ≥ 65 
(C-statistic = 0.632).
Ischemic stroke
There were 29 ischemic strokes during the 
follow-up period. Table 6 summarizes the baseline 
characteristics of patients with and without ische-
mic stroke. Apart from a higher proportion of fema-
les among patients with ischemic stroke (44.8% vs. 
23.9%, p = 0.01), there were no statistically signifi-
cant differences between patients with and without 
stroke (Table 6). In the Cox proportional hazards mo-
del, female gender, hypertension, previous stroke, 
as well as the CHADS2 and CHA2DS2-VASc scores 
were strongly associated with stroke (Table 4). 
Kaplan-Meier analysis revealed a significantly 
higher incidence of ischemic stroke in patients with 
higher CHADS2 score (Log-rank: 6.0, p = 0.014, 
Fig. 2A) and higher CHA2DS2-VASc score (Log-
-rank: 7.1, p = 0.002, Fig. 2B). The incidence of 
stroke was 0.41 per 100 patient-years in patients 
with CHADS2 = 0; 1.02 per 100 patient-years in 
Table 2. Baseline characteristics of patients stratified according to the CHA2DS2-VASc score.
CHA2D2-VASc score
 1 (n = 90) 2 (n = 141) 3 (n = 142) ≥ 4 (n = 234) P
Age [years] 51.0 ± 7.3 59.8 ± 9.2 64.3 ± 9.8 73.2 ± 7.2 < 0.001*
Female gender 0 (0%) 6 (4.3%) 21 (14.8%) 124 (53.0%) < 0.001*
Hypertension 0 (0%) 52 (36.9%) 85 (59.9%) 180 (76.9%) < 0.001*
Diabetes mellitus 0 (0%) 25 (17.7%) 65 (45.8%) 146 (62.4%) < 0.001*
Heart failure 0 (0%) 8 (5.7%) 15 (10.6%) 66 (28.2%) < 0.001*
Hypercholesterolemia 35 (38.9%) 62 (44.0%) 62 (43.7%) 108 (46.2%) 0.71
Lung disease 83 (15.1%) 130 (92.2%) 121 (85.2%) 215 (91.9%) 0.12
Significant renal impairment 2 (2.2%) 7 (5.0%) 16 (11.3%) 26 (11.1%) 0.02*
Left ventricular ejection fraction [%] 47.1 ± 9.3 47.0 ± 10.2 45.5 ± 10.8 44.2 ± 10.1 0.03*
Revascularization:
PCI 19 (21.1%) 21 (14.9%) 21 (14.8%) 39 (16.7%) 0.58
CABG 1 (1.1%) 1 (0.7%) 1 (0.7%) 2 (0.9%) 0.99
Medications:
Aspirin 88 (97.8%) 132 (93.6%) 135 (95.1%) 214 (91.5%) 0.17
ACEI 74 (82.2%) 113 (80.1%) 108 (76.1%) 185 (79.1%) 0.70
Beta-blockers 68 (75.6%) 108 (76.6%) 103 (72.5%) 163 (69.7%) 0.47
Statin 2 (2.2%) 6 (4.3%) 14 (9.9%) 27 (11.5%) 0.01*
Calcium channel blocker 74 (82.2%) 105 (74.5%) 100 (70.4%) 171 (73.1%) 0.24
*p < 0.05; CHA2DS2-VASc score — CHA2D2-Vascular disease, Age 65–74 years, Sex category score; rest abbreviations as in Table 1
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patients with CHADS2 = 1; 1.11 per 100 patient-
-years in patients with CHADS2 = 2; and 1.95 per 
100 patient-years in patients with CHADS2 ≥ 3; 
p-value for trend < 0.0001. In a similar fashion, 
the incidence of stroke also increased with the 
CHA2DS2-VASc score (CHA2DS2-VASc = 1: 0.39 
per 100 patient-years; CHA2DS2-VASc = 2: 0.49 
per 100 patient-years; CHA2DS2-VASc = 3: 1.02 
per 100 patient-years; and CHA2DS2-VASc ≥ 4: 1.48 
per 100 patient-years; p-value for trend < 0.0001). 
The C-statistic of the CHA2DS2-VASc score as 
a predictor of ischemic stroke was 0.601, superior 
to that of CHADS2 score (0.573) (Table 5). The cut-
-off value of the CHA2DS2-VASc for ischemic stroke 
was 3 (sensitivity: 79.3%; specificity: 38.9%).
Discussion
We have demonstrated that post-MI patients 
are at high risk of developing AF (2.8% per year) 
as well as ischemic stroke (0.9% per year). The 
CHADS2 and CHA2DS2-VASc scores, originally 
designed for stroke risk stratification in AF pa-
tients, have been shown to be predictive of the 
occurrence of both new AF and ischemic stroke 
in these patients. The test discrimination of the 
CHA2DS2-VASc score appears to be superior to 
the CHADS2 for both new AF and ischemic stroke. 
Such scores may thus be used in post-MI patients 
to identify those at risk of developing new AF and 
ischemic stroke in order to institute close clinical 
surveillance and early intervention.
Traditional risk factors that contribute to AF 
include increasing age [17, 18], male gender [19], 
hypertension [19], diabetes mellitus [19], obesity 
[19, 20], hyperthyroidism [16, 21, 22], congestive 
heart failure, and other structural heart diseases 
[19, 23, 24]. In addition, in the recent ECHOES 
study of a non-selected cohort of 3,960 individuals 
Table 3. Baseline characteristics of patients with or without new onset atrial fibrillation (AF).
AF (n = 83) No AF (n = 524) P
Age [years] 70.2 ± 7.8 63.8 ± 11.7 < 0.001*
Female gender 33 (39.8%) 118 (22.5%) 0.001*
Diabetes mellitus 39 (47.0%) 197 (37.6%) 0.10
Hypertension 47 (56.6%) 270 (51.5%) 0.39
Heart failure 26 (31.3%) 63 (12.0%) < 0.001*
Hypercholesterolemia 36 (43.4%) 304 (58.0%) 0.01*
Lung disease 7 (8.4%) 51 (9.7%) 0.71
Significant renal impairment 11 (13.3%) 41 (7.8%) 0.10
Left ventricular ejection fraction [%] 42.0 ± 9.6 46.2 ± 10.2 0.001*
Revascularization:
PCI 12 (14.5%) 88 (16.8%) 0.59
CABG 0 (0%) 5 (1.0%) 0.37
Mean CHADS2 score 1.71 ± 1.04 1.21 ± 0.98 < 0.001*
CHADS2 score: 0.001*
0 11 (13.3%) 144 (27.5%)
1 22 (26.5%) 181 (34.5%)
2 34 (41.0%) 147 (28.1%)
≥ 3 16 (19.3%) 52 (9.9%)
Mean CHA2DS2-VASc score 3.90 ± 1.34 2.97 ± 1.40 < 0.001*
CHA2DS2-VASc score: < 0.001*
1 2 (2.4%) 88 (16.8%)
2 13 (15.7%) 128 (24.4%)
3 14 (16.9%) 128 (24.4%)
≥ 4 54 (65.1%) 180 (34.4%)
Medications:
Aspirin 75 (90.4%) 494 (94.3%) 0.17
ACEI 67 (80.7%) 413 (78.8%) 0.69
Beta-blockers 44 (53.0%) 398 (76.0%) < 0.001*
Statin 49 (59.0%) 401 (76.5%) 0.001*
Calcium channel blocker 9 (10.8%) 40 (7.6%) 0.32
*p < 0.05; abbreviations as in Tables 1 and 2
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from the general population, subjects with a prior 
history of myocardial infarct also had a higher 
prevalence of AF at around 6%, nearly 3-fold 
higher than that of the general population [25].
Consistent with these studies, most traditional risk 
factors such as increasing age, diabetes mellitus, 
congestive heart failure, and prior stroke have been 
demonstrated to be associated with new AF in the 
present cohort of post-MI patients. Nonetheless, 
in our cohort, hypertension, one of the strongest 
risk factors of AF [9], did not appear to contribute 
to the subsequent development of AF. In stark con-
trast to previous community studies [26], female 
gender instead of male gender was shown to be 
associated with new AF in our cohort. This may 
be because hypertension and male gender are both 
Table 4. Association between baseline factors, CHADS2, and CHA2DS2-VASc scores and new atrial fi-
brillation (AF) and ischemic stroke (n = 607).
New AF Ischemic stroke
HR 95% CI P HR 95% CI P
Age > 65 2.77 1.77–4.33 0.0001 0.96 0.46–2.01 0.92
Age > 75 2.34 1.33–4.13 0.02 2.06 0.78–5.42 0.14
Female 2.32 1.39–3.87 0.002 3.11 1.33–7.28 0.009*
Hypertension 1.36 0.87–2.12 0.59 2.15 1.03–4.49 0.04
Diabetes mellitus 1.69 1.06–2.70 0.03 1.23 0.56–2.67 0.60
Heart failure 7.58 3.82–15.02 < 0.0001 1.82 0.57–5.77 0.31
Stroke 40.55 1.96–839.5 0.005 328.6 1.98–54521 0.03*
CHADS2
0 Reference Reference Reference Reference
1 2.29 1.40–3.75 0.007* 2.39 1.09–5.23 0.03*
2 3.15 1.84–5.39 0.0005* 3.02 1.12–7.76 0.02*
≥ 3 7.30 2.92–18.26 0.0001* 11.6 2.12–63.45 0.005*
CHA2DS2-VASc
1 Reference Reference Reference Reference
2 2.93 1.60–5.36 0.004* 2.04 0.78–5.40 0.15
3 3.23 1.78–5.84 0.001* 2.32 0.91–5.93 0.08
≥ 4 4.19 2.30–7.61 0.0001 3.26 1.19–8.94 0.02*
*p < 0.05; HR — hazard ratio; CI — confidence interval; rest abbreviations as in Tables 1 and 2
Figure 1. New atrial fibrillation (AF); A. Kaplan-Meier estimate of percentage of new AF stratified by the CHADS2 score; 
B. Kaplan-Meier estimate of percentage of new AF stratified by the CHA2DS2-VASc score; CHADS2 score: Congestive 
heart failure, Hypertension, Age ≥ 75 years, Diabetes, previous Stroke score; CHA2DS2-VASc score: CHA2DS2-Vascular 
disease, Age 65–74 years, Sex category score.
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Table 5. Sensitivity, specificity, and predictive ability (C-statistics and the 95% confidence interval [CI]) 
for individual risk factors, CHADS2 score and CHA2DS2VASc score in relation to new atrial fibrillation (AF) 
and ischemic stroke.
Sensitivity Specificity C-statistic (95% CI) P
New AF
Age > 75 31.3 80.5 0.559 (0.52–0.60) 0.03*
Hypertension 56.6 48.5 0.525 (0.49–0.57) 0.39
Diabetes mellitus 47.0 52.4 0.547 (0.51–0.59) 0.11
Heart failure 31.3 88.0 0.597 (0.56–0.64) 0.0003*
Stroke 2.4 99.6 0.510 (0.47–0.55) 0.24
Female gender 39.8 77.5 0.586 (0.55–0.63) 0.003*
CHADS2 0.632 (0.59–0.67) < 0.0001
CHADS2 ≥ 0 100.0 0.0
CHADS2 ≥ 1 86.8 27.5
CHADS2 ≥ 2 60.2 62.0
CHADS2 ≥ 3 19.3 90.1
CHA2DS2VASc 100.0 0.0 0.676 (0.64–0.71) < 0.0001
CHA2DS2VASc ≥ 2 97.6 16.8
CHA2DS2VASc ≥ 3 81.9 41.2
CHA2DS2VASc ≥ 4 65.1 65.7
Ischemic stroke
Age > 75 27.6 79.2 0.534 (0.49–0.57) 0.43
Hypertension 65.5 48.4 0.570 (0.53–0.61) 0.13
Diabetes mellitus 62.1 38.9 0.510 (0.46–0.55) 0.92
Heart failure 17.2 85.5 0.514 (0.47–0.55) 0.71
Stroke 3.5 99.5 0.520 (0.47–0.56) 0.40
Female gender 44.8 76.1 0.61 (0.57–0.64) 0.03*
CHADS2 0.573 (0.53–0.61) 0.15
CHADS2 ≥ 0 100.0 0.0
CHADS2 ≥ 1 86.2 26.1
CHADS2 ≥ 2 48.3 59.3
CHADS2  ≥ 3 17.2 89.1
CHA2DS2VASc 0.601 (0.56–0.64) 0.03*
CHA2DS2VASc ≥ 1 100.0 0.0
CHA2DS2VASc ≥ 2 93.1 15.2
CHA2DS2VASc ≥ 3 79.3 38.9
CHA2DS2VASc ≥ 4 51.7 62.1
*p < 0.05; abbreviations as in Tables 1 and 2
strong risk factors for coronary artery disease and 
contribute at least partly to the development of AF 
through myocardial ischemia. As all the subjects 
in the current cohort had prior MI in contrast to 
previous community studies in which only a mi-
nority of subjects had established coronary artery 
disease, the contributory effects of hypertension 
and male gender to AF development may thus be 
attenuated. Nonetheless, while these individual 
risk factors have been unequivocally shown to 
predispose to new AF, they lack sensitivity and/ 
/or specificity to identify high-risk individuals. 
For instance, the sensitivity of these individual 
components such as age of more than 75 years, 
diabetes mellitus, congestive heart failure and prior 
ischemic stroke ranges from 2.4% to 79.5%, with 
the corresponding C-statistic only slightly better 
than that of chance. Amongst patients with AF, 
the CHADS2 and CHA2DS2VASc scores have been 
validated, most recently amongst the Chinese [27], 
and are currently widely used stratification tools 
to estimate the risk of stroke, thus guiding the 
decision for long-term anticoagulation. These sco-
res, nevertheless, also represent a panel of most 
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Table 6. Baseline characteristics of patients with or without stroke.
Stroke (n = 29) No stroke (n = 578) P
Age [years] 66.9 ± 9.7 64.6 ± 11.5 0.28
Female gender 13 (44.8%) 138 (23.9%) 0.01*
Diabetes mellitus 11 (37.9%) 225 (38.9%) 0.91
Hypertension 19 (65.5%) 298 (51.6%) 0.14
Heart failure 5 (17.2%) 84 (14.5%) 0.69
Hypercholesterolemia 13 (44.8%) 254 (43.9%) 0.93
Lung disease 1 (3.4%) 57 (9.9%) 0.25
Significant renal impairment 3 (10.3%) 49 (8.5%) 0.73
Left ventricular ejection fraction [%] 48.2 ± 8.0 45.5 ± 10.3 0.09
Revascularization:
PCI 7 (24.1%) 93 (16.1%) 0.25
CABG 0 (0%) 5 (0.9%) 0.62
Mean CHADS2 score 1.55 ± 1.02 1.27 ± 1.00 0.14
CHADS2 score: 0.15
0 4 (13.9%) 151 (26.1%)
1 11 (37.9%) 192 (33.2%)
2 9 (31.0%) 172 (29.8%)
≥ 3 5 (17.2%) 63 (10.9%)
Mean CHA2DS2-VASc score 3.55 ± 1.37 3.07 ± 1.43 0.08
CHA2DS2-VASc score: 0.05
1 2 (6.9%) 88 (15.2%)
2 4 (13.8%) 137 (23.7%)
3 8 (27.6%) 134 (23.2%)
≥ 4 15 (51.7%) 219 (37.9%)
Medications:
Aspirin 26 (89.7%) 543 (93.9%) 0.35
ACEI 24 (82.8%) 456 (78.9%) 0.62
Beta-blockers 24 (82.8%) 418 (72.3%) 0.22
Statin 19 (65.5%) 431 (74.6%) 0.28
Calcium channel blocker 3 (10.3%) 46 (8.0%) 0.65
*p < 0.05; abbreviations as in Tables 1 and 2
Figure 2. Ischemic stroke; A. Kaplan-Meier estimate of percentage of new atrial fibrillation (AF) stratified by the 
CHADS2 score; B. Kaplan-Meier estimate of percentage of new AF stratified by the CHA2DS2-VASc score; CHADS2 
score: Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes, previous Stroke score; CHA2DS2-VASc score: 
CHA2DS2-Vascular disease, Age 65–74 years, Sex category score.
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common co-morbidities that predispose to AF; it 
is conceivable that their inclusion in these scores 
can collectively improve the predictive power of 
new onset AF and stroke.
The results of our study have several impor-
tant clinical implications. First, the co-occurrence 
of MI and AF often represents a challenging 
management problem to the attending physician, 
particularly when coronary stenting is required. 
For patients with pre-existing AF who develo-
ped MI and were undergoing coronary stenting, 
current guidelines recommend a combination of 
aspirin, clopidogrel, and oral anticoagulation, the 
so-called triple therapy [7, 28]. This is because the 
dual antiplatelet therapy, (aspirin and clopidogrel) 
essential to prevent stent thrombosis, has been 
proven inferior to warfarin for the prevention of 
AF-related ischemic stroke [29, 30]. Nevertheless, 
as prolonged triple therapy (1 year) is associated 
with an excessive major bleeding risk [31–33], the 
duration of such therapy should be shortened in 
order to avoid/minimize bleeding complications. 
The use of drug-eluting stents in such patients 
is thus discouraged [28]. Among patients with no 
pre-existing AF, a drug-eluting stent is often the 
preferred stent of many interventional cardiolo-
gists given the advantages of a small reduction of 
target vessel revascularization over bare-metal 
stents [34, 35]. In the present study, despite the 
lack of previously documented AF, patients with 
MI and a CHADS2, score of ≥ 3 had an exceedingly 
high risk of new AF: 7.03%, i.e., around ~1 in 14 
patients per year. Similarly, the incidence of new 
AF in patients with a CHA2DS2-VASc score of ≥ 4 
was as high as 5.83% per years (~1 in 17 patients 
per year). The occurrence of new AF, particularly 
during the first year after MI and drug-eluting 
stent implantation can be problematic. Attending 
physicians often face a therapeutic dilemma to 
either initiate a prolonged course of triple therapy 
that imposes an excessive bleeding risk, or to leave 
patients unprotected from the high ischemic stroke 
risk [36]. In addition to the risk factors for in-stent 
restenosis such as vessel size and concomitant 
diabetes mellitus, the choice of stents in patients 
with MI may also take into account the likelihood of 
the development of new AF according to the simple 
CHADS2, and CHA2DS2-VASc scores. It would be 
important to evaluate the “net clinical benefit” of 
a drug-eluting stent with a small reduction in target 
vessel revascularization, balancing the excessive 
bleeding risk of triple therapy deemed necessary 
to minimize ischemic stroke risk as new AF en-
sues. For the longer term, in those patients with 
increased CHA2DS2 or CHA2DS2-VASc score, more 
intense follow-up, including repeated 24 h ECG 
monitoring or even an implantable device [13] may 
allow early detection of the occurrence as well as 
the burden of AF, and thus allow implementation 
of effective preventive measures including anti-
-coagulation in high-risk subjects.
Limitations of the study
This study had several limitations. First, 
asymptomatic episodes of AF were not assessed 
routinely by ambulatory ECG monitoring or im-
plantable device. The lack of routine 24 h ambula-
tory ECG monitoring was one of the major short-
comings of this work. As all patients in the present 
cohort had an acute STEMI and thus represented 
a very special patient population, extrapolation 
of our results to other patient populations may 
be inappropriate. Nonetheless, the current study 
provides novel data that support the potential use 
of CHA2DS2-VASc score in post-MI patients to 
stratify their risk of new AF and ischemic stroke.
Conclusions
The CHADS2 and CHA2DS2-VASc scores can 
identify post-STEMI patients at high risk of AF and 
ischemic stroke. This enables close surveillance 
and prompt anticoagulation for stroke prevention.
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